

THERAVANCE INC  
Form SC 14D9  
August 01, 2007

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549



## **SCHEDULE 14D-9**



**Solicitation/Recommendation Statement under Section 14(d)(4)**

**of the Securities Exchange Act of 1934**





**Theravance, Inc.**

(Name of Subject Company)



**Theravance, Inc.**

(Names of Persons Filing Statement)



**Common Stock, par value \$0.01 per share**

(Title of Class of Securities)





88338T 10 4

(CUSIP Number of Class of Securities)



**Rick E Winningham**

**Chief Executive Officer**

**Theravance, Inc.**

**901 Gateway Boulevard**



**South San Francisco, CA 94080**

**(650) 808-6000**

Edgar Filing: THERAVANCE INC - Form SC 14D9

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of the persons filing statement)



With a copy to:



**Christopher D. Dillon, Esq.**

**John Dietz, Esq.**



**Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP**

**155 Constitution Drive**

**Menlo Park, CA 94025**

**(650) 321-2400**

o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

---

**Item 1. Subject Company Information**

The name of the subject company is Theravance, Inc. ( Theravance ).

(a) Reference is made to the information set forth under *Certain Information Concerning Theravance* in the Notice of Put Right, which is filed herewith as Exhibit (a)(1)(i) and incorporated herein by reference.

(b) Reference is made to the information set forth under *Background of Theravance* in the Notice of Put Right, which is incorporated herein by reference.

**Item 2. Identity and Background of Filing Person**

(a) Reference is made to the information set forth under *Certain Information Concerning Theravance* in the Notice of Put Right, which is incorporated herein by reference.

(d) This statement is filed in connection with the notice to holders of Theravance Common Stock, par value \$0.01 per share (the Common Shares ), of their right to cause Theravance to purchase the Common Shares at a price of \$19.375 per Common Share in cash on the terms set forth in the Notice of Put Right, which is incorporated herein by reference.

**Item 3. Past Contacts, Transactions, Negotiations and Agreements**

Reference is made to the information set forth under *Background on the Put Right, The Put Right - GSK's Obligation to Provide Funds to Purchase Common Shares*, and *Appendix B - Certain Additional Information About Theravance* in the Notice of Put Right, which is incorporated herein by reference. Reference is made to the Amended and Restated Governance Agreement attached hereto as Exhibit (e)(1), and the Amendment to the Amended and Restated Governance Agreement attached hereto as Exhibit (e)(2), both of which are incorporated herein by reference.

**Item 4. The Solicitation or Recommendation**

Reference is made to the information set forth under *Questions and Answers About the Put Right* and *Certain Information Concerning Theravance* in the Notice of Put Right, which is incorporated herein by reference. The Board of Directors of Theravance is not making any recommendation regarding the Put Right.

Reference is made to the information set forth under *Certain Information Concerning Theravance* in the Notice of Put Right, which is incorporated herein by reference, for information concerning officers, directors or affiliates of Dreyer s who intend to exercise the Put Right and require Dreyer s to purchase Common Shares that are held beneficially or of record by such persons.

**Item 5. Person/Assets, Retained, Employed, Compensated or Used**

Reference is made to the information set forth under *Fees and Expenses; Persons Used, Certain Information Concerning Theravance* and *Certain Legal Matters - Miscellaneous* in the Notice of Put Right, which is incorporated herein by reference.

**Item 6. Interest in Securities of the Subject Company**

Reference is made to the information set forth under *Background on the Put Right* and *Certain Information Concerning Theravance* in the Notice of Put Right, which is incorporated herein by reference.

**Item 7. Purposes of the Transaction and Plans or Proposals**

Reference is made to the information set forth under *Summary Term Sheet, Background of Theravance, Background on the Put Right, The Put Right*, and *Certain Legal Matters* in the Notice of Put Right, which is incorporated herein by reference.

**Item 8. Additional Information**

Reference is made to the Letter of Transmittal, which is incorporated herein by reference.



**Item 9. Exhibits**



Edgar Filing: THERAVANCE INC - Form SC 14D9

- (a)(1)(i) Notice of Put Right dated August 1, 2007.
- (a)(1)(ii) Letter of Transmittal.
- (a)(1)(iii) Notice of Guaranteed Delivery.
- (a)(1)(iv) Substitute W-9 Guidelines.
- (a)(1)(v) Summary Advertisement to be published on August 1, 2007.
- (e)(1) Amended and Restated Governance Agreement dated as of June 4, 2004 by and among Theravance, SmithKline Beecham Corporation, GlaxoSmithKline plc, and Glaxo Group Limited.(1)
- (e)(2) Amendment to the Amended and Restated Governance Agreement, dated as of May 11, 2007 by and among SmithKline Beecham Corporation, Theravance, GlaxoSmithKline plc and Glaxo Group Limited.
- (e)(3) Restated Certificate of Incorporation of Theravance, Inc.(2)
- (e)(4) Form of Indemnification Agreement for Directors and Officers of Theravance, Inc.(3)
- (e)(5) Theravance, Inc. Stock Option Plan(1997), as amended.(4)
- (e)(6) Long-Term Stock Option Plan.(5)
- (e)(7) 2004 Equity Incentive Plan.(6)
- (e)(8) Employee Stock Purchase Plan.(7)
- (e)(9) Amended and Restated Change in Control Severance Plan.(8)
- (e)(10) Offer Letter with Rick E Winningham dated August 23, 2001.(9)
- (e)(11) Full Recourse Note Secured by Deed of Trust and Stock Pledge issued by Rick E Winningham to the registrant, dated as of July 1, 2002.(10)
- (e)(12) Stock Pledge Agreement between the registrant and Rick E Winningham, dated as of July 1, 2002.(11)
- (e)(13) Letter Agreement between the registrant and Rick E Winningham, dated as of June 4, 2004.(12)
- (e)(14) Offer Letter with Patrick P.A. Humphrey dated April 6, 2001.(13)
- (e)(15) Full Recourse Note Secured by Deed of Trust and Stock Pledge issued by Patrick P.A. Humphrey to the registrant, dated as of February 27, 2002.(14)
- (e)(16) Stock Pledge Agreement between the registrant and Patrick P.A. Humphrey, dated as of February 27, 2002.(15)
- (e)(17) Letter Agreement between the registrant and Patrick P.A. Humphrey dated June 4, 2004.(16)
- (e)(18) Offer Letter with David L. Brinkley dated June 30, 2000.(17)
- (e)(19) Offer Letter with Michael W. Aguiar dated as of January 31, 2005.(18)
- (e)(20) Form of Notice of Grant and Stock Option Agreement under 2004 Equity Incentive Plan.(19)
- (e)(21) Form of Stock Restriction Agreement under 2004 Equity Incentive Plan.(20)

Edgar Filing: THERAVANCE INC - Form SC 14D9

(e)(22) Description of Cash Bonus Program, as amended.(21)

(e)(23) Stock Option Agreement between the Company and P. Roy Vagelos dated as of April 26, 2006.(22)

(g) None

---



- (1) Incorporated herein by reference to exhibit 10.14 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (2) Incorporated herein by reference to exhibit 3.3 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (3) Incorporated herein by reference to exhibit 10.11 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (4) Incorporated herein by reference to exhibit 10.1 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (5) Incorporated herein by reference to exhibit 10.2 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (6) Incorporated herein by reference to exhibit 10.3 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (7) Incorporated herein by reference to exhibit 10.4 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (8) Incorporated herein by reference to exhibit 10.5 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (9) Incorporated herein by reference to exhibit 10.17 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (10) Incorporated herein by reference to exhibit 10.22 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (11) Incorporated herein by reference to exhibit 10.23 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (12) Incorporated herein by reference to exhibit 10.20 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (13) Incorporated herein by reference to exhibit 10.21 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (14) Incorporated herein by reference to exhibit 10.22 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (15) Incorporated herein by reference to exhibit 10.23 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (16) Incorporated herein by reference to exhibit 10.24 in the Company's Registration Statement on Form S-1 (No. 333-116384).
- (17) Incorporated herein by reference to exhibit 10.25 in the Company's Registration Statement on Form S-1 (No. 333-116384).

- (18) Incorporated herein by reference to exhibit 10.29 in the Company's Registration Statement on Form S-1 (No. 333-116384).
  - (19) Incorporated herein by reference to exhibit 10.30 in the Company's Registration Statement on Form S-1 (No. 333-116384).
  - (20) Incorporated herein by reference to exhibit 10.31 in the Company's Registration Statement on Form S-1 (No. 333-116384).
  - (21) Incorporated herein by reference to exhibit 10.32 in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006.
  - (22) Incorporated herein by reference to the exhibit to the Company's Current Report on Form 8-K filed on May 2, 2006.
-

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**THERAVANCE, INC.**

By: /s/ RICK E WINNINGHAM  
Name: Rick E Winningham  
Title: Chief Executive Officer

Dated: August 1, 2007

---